Selective PAK1 Degradation Using CRBN-Recruiting PROTACs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecule inhibitors for PAK1 exhibit limited selectivity and stability, failing to effectively target and degrade PAK1 over other PAKs, particularly PAK2, and are ineffective at micromolar doses.
Innovation Solution
Development of PAK1 degraders, specifically proteolysis-targeting chimeric molecules (PROTACs) that link NVS-PAK1-1 to a degron via a linker, utilizing an E3 ubiquitin ligase ligand like CRBN, to selectively degrade PAK1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If small molecule inhibitors like NVS-PAK1-1 are used to target PAK1, then selectivity for PAK1 over PAK2 is improved, but stability and half-life in vivo are worsened due to metabolism by cytochrome P450 system
Solution Approach 1:
The patent combines a PAK1-specific inhibitor (NVS-PAK1-1) with an E3 ubiquitin ligase ligand (degron) to create a PROTAC molecule. This merging allows the compound to simultaneously bind PAK1 with high selectivity and recruit the ubiquitin-proteasome system for degradation, thereby maintaining selectivity while improving in vivo stability and potency through targeted degradation rather than reversible inhibition.
Solution Approach 2:
The PROTAC molecule acts as an intermediary that bridges PAK1 and the E3 ubiquitin ligase system. By incorporating a degron that binds to CRBN (an E3 ligase), the molecule mediates the recruitment of the proteasome to degrade PAK1, thereby overcoming the metabolic instability of traditional inhibitors while maintaining their selective binding properties.
2Reliability
If small molecule inhibitors bind to the catalytic domain of PAK1, then inhibition is achieved, but selectivity over PAK2 is worsened due to 93% identity in catalytic domains
Solution Approach 1:
The PROTAC molecule is segmented into distinct functional modules: a PAK1-binding warhead (NVS-PAK1-1) that provides selective recognition, a linker that connects the warhead to the degron, and the degron module that recruits E3 ligases. This segmentation allows the PAK1-specific binding properties to be preserved while adding the degradation function, achieving both reliable inhibition and high selectivity.
Solution Approach 2:
The PROTAC is a composite molecule combining two distinct pharmacophores: the PAK1-inhibiting warhead and the E3 ligase-recruiting degron. This composite structure allows the molecule to exhibit both PAK1-specific binding (from the warhead) and targeted degradation (from the degron), thereby achieving reliable inhibition with high selectivity that neither component could achieve alone.
3Measurement precision
If compounds bind to the p21-binding domain at the N-terminus of PAK1, then selectivity for PAK1 over PAK2 is improved, but potency is worsened requiring micromolar doses
Solution Approach 1:
The PROTAC merges the selective binding capability (from p21-binding domain targeting) with the potent degradation mechanism of the ubiquitin-proteasome system. By combining a selective PAK1 binder with a degron that recruits E3 ligases, the molecule achieves both high selectivity and high potency through irreversible degradation rather than reversible binding, overcoming the micromolar dose requirement.
Solution Approach 2:
The invention changes the mechanism of action parameter from reversible inhibition to irreversible degradation. By utilizing the ubiquitin-proteasome pathway, the PROTAC induces permanent removal of PAK1 protein, thereby dramatically increasing potency compared to reversible inhibitors that require micromolar concentrations for sustained effect, while maintaining the selectivity advantages of p21-binding domain targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PAK1 degraders achieve selective and efficient degradation of PAK1, suppressing its aberrant activity and associated diseases such as cancer, with improved potency and stability compared to previous inhibitors.
Implementation Method 1
the PAK1 degrader comprises NVS-PAK1-1 linked to a degron, optionally via a linker... the degron is a ligand for an E3 ubiquitin ligase such as CRBN
Data Source
AI summary
PAK1 degraders and methods of use thereof are disclosed.